APO Research
Talk to an analyst

APO RESEARCH · REPORT

Medications for Chronic Pain Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Medications for Chronic Pain Treatment Market Outlook and Growth Opportunities 2026

22 December 2025202 pages

Choose your research edition.

Industry ResearchMedications for Chronic Pain Treatment Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Medications for Chronic Pain Treatment Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Medications for Chronic Pain Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medications for Chronic Pain Treatment Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Medications for Chronic Pain Treatment Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Medications for Chronic Pain Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Medications for Chronic Pain Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Medications for Chronic Pain Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Medications for Chronic Pain Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Medications for Chronic Pain Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Medications for Chronic Pain Treatment market include YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD., Southwest Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., REYOUNG, Johnson and Johnson Services Inc., Novartis AG, Merck & Co., Jiangsu Hengrui Medicine Co,.Ltd and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Medications for Chronic Pain Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Medications for Chronic Pain Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Medications for Chronic Pain Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Medications for Chronic Pain Treatment market.

Medications for Chronic Pain Treatment Segment by Company

YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.

Southwest Pharmaceutical Co., Ltd.

Teva Pharmaceutical Industries Ltd.

REYOUNG

Johnson and Johnson Services Inc.

Novartis AG

Merck & Co.

Jiangsu Hengrui Medicine Co,.Ltd

Pfizer

GlaxoSmithKline plc.

BAYER

AstraZeneca plc.

Purdue Pharma L.P.

Endo International plc.

Depomed

Abbott Laboratories

Medications for Chronic Pain Treatment Segment by Type

Nonopioid

Opioids

Medications for Chronic Pain Treatment Segment by Application

Hospital

Pharmacy

Other

Medications for Chronic Pain Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Medications for Chronic Pain Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Medications for Chronic Pain Treatment key companies, revenue, market share, and recent developments.

3. To split the Medications for Chronic Pain Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Medications for Chronic Pain Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Medications for Chronic Pain Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Medications for Chronic Pain Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medications for Chronic Pain Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medications for Chronic Pain Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medications for Chronic Pain Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Medications for Chronic Pain Treatment industry.

Chapter 3: Detailed analysis of Medications for Chronic Pain Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Medications for Chronic Pain Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Medications for Chronic Pain Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Medications for Chronic Pain Treatment Industry Trends Table 2. Medications for Chronic Pain Treatment Industry Drivers Table 3. Medications for Chronic Pain Treatment Industry Opportunities and Challenges Table 4. Medications for Chronic Pain Treatment Industry Restraints Table 5. Global Medications for Chronic Pain Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Medications for Chronic Pain Treatment Revenue Share by Company (2021-2026) Table 7. Global Medications for Chronic Pain Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Medications for Chronic Pain Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Medications for Chronic Pain Treatment Company, Product Type & Application Table 10. Global Medications for Chronic Pain Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Medications for Chronic Pain Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Nonopioid Table 15. Significant Companies of Opioids Table 16. Global Medications for Chronic Pain Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Medications for Chronic Pain Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Medications for Chronic Pain Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Medications for Chronic Pain Treatment Sales Value Share by Type (2021-2026) Table 20. Global Medications for Chronic Pain Treatment Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Pharmacy Table 23. Significant Companies of Other Table 24. Global Medications for Chronic Pain Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Medications for Chronic Pain Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Medications for Chronic Pain Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Medications for Chronic Pain Treatment Sales Value Share by Application (2021-2026) Table 28. Global Medications for Chronic Pain Treatment Sales Value Share by Application (2027-2032) Table 29. Global Medications for Chronic Pain Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Medications for Chronic Pain Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Medications for Chronic Pain Treatment Sales Value Share by Region (2021-2026) Table 32. Global Medications for Chronic Pain Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Medications for Chronic Pain Treatment Sales Value Share by Region (2027-2032) Table 34. Global Medications for Chronic Pain Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Medications for Chronic Pain Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Medications for Chronic Pain Treatment Sales Value Market Share by Country (2021-2026) Table 37. Global Medications for Chronic Pain Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Medications for Chronic Pain Treatment Sales Value Market Share by Country (2027-2032) Table 39. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Company Information Table 40. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Business Overview Table 41. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Medications for Chronic Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Medications for Chronic Pain Treatment Product Portfolio Table 43. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Recent Development Table 44. Southwest Pharmaceutical Co., Ltd. Company Information Table 45. Southwest Pharmaceutical Co., Ltd. Business Overview Table 46. Southwest Pharmaceutical Co., Ltd. Medications for Chronic Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Southwest Pharmaceutical Co., Ltd. Medications for Chronic Pain Treatment Product Portfolio Table 48. Southwest Pharmaceutical Co., Ltd. Recent Development Table 49. Teva Pharmaceutical Industries Ltd. Company Information Table 50. Teva Pharmaceutical Industries Ltd. Business Overview Table 51. Teva Pharmaceutical Industries Ltd. Medications for Chronic Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Teva Pharmaceutical Industries Ltd. Medications for Chronic Pain Treatment Product Portfolio Table 53. Teva Pharmaceutical Industries Ltd. Recent Development Table 54. REYOUNG Company Information Table 55. REYOUNG Business Overview Table 56. REYOUNG Medications for Chronic Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. REYOUNG Medications for Chronic Pain Treatment Product Portfolio Table 58. REYOUNG Recent Development Table 59. Johnson and Johnson Services Inc. Company Information Table 60. Johnson and Johnson Services Inc. Business Overview Table 61. Johnson and Johnson Services Inc. Medications for Chronic Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Johnson and Johnson Services Inc. Medications for Chronic Pain Treatment Product Portfolio Table 63. Johnson and Johnson Services Inc. Recent Development Table 64. Novartis AG Company Information Table 65. Novartis AG Business Overview Table 66. Novartis AG Medications for Chronic Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Novartis AG Medications for Chronic Pain Treatment Product Portfolio Table 68. Novartis AG Recent Development Table 69. Merck & Co. Company Information Table 70. Merck & Co. Business Overview Table 71. Merck & Co. Medications for Chronic Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Merck & Co. Medications for Chronic Pain Treatment Product Portfolio Table 73. Merck & Co. Recent Development Table 74. Jiangsu Hengrui Medicine Co,.Ltd Company Information Table 75. Jiangsu Hengrui Medicine Co,.Ltd Business Overview Table 76. Jiangsu Hengrui Medicine Co,.Ltd Medications for Chronic Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Jiangsu Hengrui Medicine Co,.Ltd Medications for Chronic Pain Treatment Product Portfolio Table 78. Jiangsu Hengrui Medicine Co,.Ltd Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Medications for Chronic Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Medications for Chronic Pain Treatment Product Portfolio Table 83. Pfizer Recent Development Table 84. GlaxoSmithKline plc. Company Information Table 85. GlaxoSmithKline plc. Business Overview Table 86. GlaxoSmithKline plc. Medications for Chronic Pain Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline plc. Medications for Chronic Pain Treatment Product Portfolio Table 88. GlaxoSmithKline plc. Recent Development Table 89. BAYER Company Information Table 90. BAYER Business Overview Table 91. BAYER Medications for Chronic Pain Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. BAYER Medications for Chronic Pain Treatment Product Portfolio Table 93. BAYER Recent Development Table 94. AstraZeneca plc. Company Information Table 95. AstraZeneca plc. Business Overview Table 96. AstraZeneca plc. Medications for Chronic Pain Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. AstraZeneca plc. Medications for Chronic Pain Treatment Product Portfolio Table 98. AstraZeneca plc. Recent Development Table 99. Purdue Pharma L.P. Company Information Table 100. Purdue Pharma L.P. Business Overview Table 101. Purdue Pharma L.P. Medications for Chronic Pain Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Purdue Pharma L.P. Medications for Chronic Pain Treatment Product Portfolio Table 103. Purdue Pharma L.P. Recent Development Table 104. Endo International plc. Company Information Table 105. Endo International plc. Business Overview Table 106. Endo International plc. Medications for Chronic Pain Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Endo International plc. Medications for Chronic Pain Treatment Product Portfolio Table 108. Endo International plc. Recent Development Table 109. Depomed Company Information Table 110. Depomed Business Overview Table 111. Depomed Medications for Chronic Pain Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Depomed Medications for Chronic Pain Treatment Product Portfolio Table 113. Depomed Recent Development Table 114. Abbott Laboratories Company Information Table 115. Abbott Laboratories Business Overview Table 116. Abbott Laboratories Medications for Chronic Pain Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Abbott Laboratories Medications for Chronic Pain Treatment Product Portfolio Table 118. Abbott Laboratories Recent Development Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Medications for Chronic Pain Treatment Product Image Figure 2. Global Medications for Chronic Pain Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medications for Chronic Pain Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Medications for Chronic Pain Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Nonopioid Image Figure 8. Opioids Image Figure 9. Global Medications for Chronic Pain Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Medications for Chronic Pain Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Medications for Chronic Pain Treatment Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Pharmacy Image Figure 14. Other Image Figure 15. Global Medications for Chronic Pain Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Medications for Chronic Pain Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Medications for Chronic Pain Treatment Sales Value Share by Application (2021-2032) Figure 18. Global Medications for Chronic Pain Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Medications for Chronic Pain Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Medications for Chronic Pain Treatment Sales Value (2021-2032) & (US$ Million) Figure 21. North America Medications for Chronic Pain Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Medications for Chronic Pain Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Medications for Chronic Pain Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Medications for Chronic Pain Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Medications for Chronic Pain Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Medications for Chronic Pain Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. South America Medications for Chronic Pain Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Medications for Chronic Pain Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Medications for Chronic Pain Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Nonopioid
  • Opioids
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.
  • Southwest Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • REYOUNG
  • Johnson and Johnson Services Inc.
  • Novartis AG
  • Merck & Co.
  • Jiangsu Hengrui Medicine Co,.Ltd
  • Pfizer
  • GlaxoSmithKline plc.
  • BAYER
  • AstraZeneca plc.
  • Purdue Pharma L.P.
  • Endo International plc.
  • Depomed
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Medications for Chronic Pain Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Medications for Chronic Pain Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Medications for Chronic Pain Treatment Market Dynamics
  1. 2.1 Medications for Chronic Pain Treatment Industry Trends
  2. 2.2 Medications for Chronic Pain Treatment Industry Drivers
  3. 2.3 Medications for Chronic Pain Treatment Industry Opportunities and Challenges
  4. 2.4 Medications for Chronic Pain Treatment Industry Restraints
3 Medications for Chronic Pain Treatment Market by Company
  1. 3.1 Global Medications for Chronic Pain Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Medications for Chronic Pain Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Medications for Chronic Pain Treatment Company Ranking (2024-2026)
  4. 3.4 Global Medications for Chronic Pain Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Medications for Chronic Pain Treatment Company Product Type and Application
  6. 3.6 Global Medications for Chronic Pain Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Medications for Chronic Pain Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Medications for Chronic Pain Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Medications for Chronic Pain Treatment Market by Type
  1. 4.1 Medications for Chronic Pain Treatment Type Introduction
  2. 4.1.1 Nonopioid
  3. 4.1.2 Opioids
  4. 4.2 Global Medications for Chronic Pain Treatment Sales Value by Type
  5. 4.2.1 Global Medications for Chronic Pain Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Medications for Chronic Pain Treatment Sales Value by Type (2021-2032)
  7. 4.2.3 Global Medications for Chronic Pain Treatment Sales Value Share by Type (2021-2032)
5 Medications for Chronic Pain Treatment Market by Application
  1. 5.1 Medications for Chronic Pain Treatment Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Medications for Chronic Pain Treatment Sales Value by Application
  6. 5.2.1 Global Medications for Chronic Pain Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Medications for Chronic Pain Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Medications for Chronic Pain Treatment Sales Value Share by Application (2021-2032)
6 Medications for Chronic Pain Treatment Regional Value Analysis
  1. 6.1 Global Medications for Chronic Pain Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Medications for Chronic Pain Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Medications for Chronic Pain Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Medications for Chronic Pain Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Medications for Chronic Pain Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Medications for Chronic Pain Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Medications for Chronic Pain Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Medications for Chronic Pain Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Medications for Chronic Pain Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Medications for Chronic Pain Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Medications for Chronic Pain Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Medications for Chronic Pain Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Medications for Chronic Pain Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Medications for Chronic Pain Treatment Sales Value Share by Country, 2025 VS 2032
7 Medications for Chronic Pain Treatment Country-level Value Analysis
  1. 7.1 Global Medications for Chronic Pain Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Medications for Chronic Pain Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Medications for Chronic Pain Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Medications for Chronic Pain Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Medications for Chronic Pain Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Medications for Chronic Pain Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Medications for Chronic Pain Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.
  2. 8.1.1 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Company Information
  3. 8.1.2 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Business Overview
  4. 8.1.3 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Medications for Chronic Pain Treatment Product Portfolio
  6. 8.1.5 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Recent Developments
  7. 8.2 Southwest Pharmaceutical Co., Ltd.
  8. 8.2.1 Southwest Pharmaceutical Co., Ltd. Company Information
  9. 8.2.2 Southwest Pharmaceutical Co., Ltd. Business Overview
  10. 8.2.3 Southwest Pharmaceutical Co., Ltd. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Southwest Pharmaceutical Co., Ltd. Medications for Chronic Pain Treatment Product Portfolio
  12. 8.2.5 Southwest Pharmaceutical Co., Ltd. Recent Developments
  13. 8.3 Teva Pharmaceutical Industries Ltd.
  14. 8.3.1 Teva Pharmaceutical Industries Ltd. Company Information
  15. 8.3.2 Teva Pharmaceutical Industries Ltd. Business Overview
  16. 8.3.3 Teva Pharmaceutical Industries Ltd. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva Pharmaceutical Industries Ltd. Medications for Chronic Pain Treatment Product Portfolio
  18. 8.3.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  19. 8.4 REYOUNG
  20. 8.4.1 REYOUNG Company Information
  21. 8.4.2 REYOUNG Business Overview
  22. 8.4.3 REYOUNG Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 REYOUNG Medications for Chronic Pain Treatment Product Portfolio
  24. 8.4.5 REYOUNG Recent Developments
  25. 8.5 Johnson and Johnson Services Inc.
  26. 8.5.1 Johnson and Johnson Services Inc. Company Information
  27. 8.5.2 Johnson and Johnson Services Inc. Business Overview
  28. 8.5.3 Johnson and Johnson Services Inc. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson and Johnson Services Inc. Medications for Chronic Pain Treatment Product Portfolio
  30. 8.5.5 Johnson and Johnson Services Inc. Recent Developments
  31. 8.6 Novartis AG
  32. 8.6.1 Novartis AG Company Information
  33. 8.6.2 Novartis AG Business Overview
  34. 8.6.3 Novartis AG Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis AG Medications for Chronic Pain Treatment Product Portfolio
  36. 8.6.5 Novartis AG Recent Developments
  37. 8.7 Merck & Co.
  38. 8.7.1 Merck & Co. Company Information
  39. 8.7.2 Merck & Co. Business Overview
  40. 8.7.3 Merck & Co. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck & Co. Medications for Chronic Pain Treatment Product Portfolio
  42. 8.7.5 Merck & Co. Recent Developments
  43. 8.8 Jiangsu Hengrui Medicine Co,.Ltd
  44. 8.8.1 Jiangsu Hengrui Medicine Co,.Ltd Company Information
  45. 8.8.2 Jiangsu Hengrui Medicine Co,.Ltd Business Overview
  46. 8.8.3 Jiangsu Hengrui Medicine Co,.Ltd Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Jiangsu Hengrui Medicine Co,.Ltd Medications for Chronic Pain Treatment Product Portfolio
  48. 8.8.5 Jiangsu Hengrui Medicine Co,.Ltd Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Medications for Chronic Pain Treatment Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 GlaxoSmithKline plc.
  56. 8.10.1 GlaxoSmithKline plc. Company Information
  57. 8.10.2 GlaxoSmithKline plc. Business Overview
  58. 8.10.3 GlaxoSmithKline plc. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline plc. Medications for Chronic Pain Treatment Product Portfolio
  60. 8.10.5 GlaxoSmithKline plc. Recent Developments
  61. 8.11 BAYER
  62. 8.11.1 BAYER Company Information
  63. 8.11.2 BAYER Business Overview
  64. 8.11.3 BAYER Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 BAYER Medications for Chronic Pain Treatment Product Portfolio
  66. 8.11.5 BAYER Recent Developments
  67. 8.12 AstraZeneca plc.
  68. 8.12.1 AstraZeneca plc. Company Information
  69. 8.12.2 AstraZeneca plc. Business Overview
  70. 8.12.3 AstraZeneca plc. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AstraZeneca plc. Medications for Chronic Pain Treatment Product Portfolio
  72. 8.12.5 AstraZeneca plc. Recent Developments
  73. 8.13 Purdue Pharma L.P.
  74. 8.13.1 Purdue Pharma L.P. Company Information
  75. 8.13.2 Purdue Pharma L.P. Business Overview
  76. 8.13.3 Purdue Pharma L.P. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Purdue Pharma L.P. Medications for Chronic Pain Treatment Product Portfolio
  78. 8.13.5 Purdue Pharma L.P. Recent Developments
  79. 8.14 Endo International plc.
  80. 8.14.1 Endo International plc. Company Information
  81. 8.14.2 Endo International plc. Business Overview
  82. 8.14.3 Endo International plc. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Endo International plc. Medications for Chronic Pain Treatment Product Portfolio
  84. 8.14.5 Endo International plc. Recent Developments
  85. 8.15 Depomed
  86. 8.15.1 Depomed Company Information
  87. 8.15.2 Depomed Business Overview
  88. 8.15.3 Depomed Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Depomed Medications for Chronic Pain Treatment Product Portfolio
  90. 8.15.5 Depomed Recent Developments
  91. 8.16 Abbott Laboratories
  92. 8.16.1 Abbott Laboratories Company Information
  93. 8.16.2 Abbott Laboratories Business Overview
  94. 8.16.3 Abbott Laboratories Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Abbott Laboratories Medications for Chronic Pain Treatment Product Portfolio
  96. 8.16.5 Abbott Laboratories Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst